Enbio KRX:352940KOSDAQ
인바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked7since Sep 11
In Q2 2026, Enbio reported revenue of ₩10.4bn, up 22.5% year on year, and operating profit of ₩172m. Enbio (인바이오) appeared in 0 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Sep 21 with 1 article. It was most often mentioned alongside Lotte Reit and Samyung Trading.
Filing signals Turnaround Screener
Enbio quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩10.4bn | +22.5% | ₩172m margin 1.6% | −₩41m |
| Q1 2026 | ₩14.1bn | +2.2% | ₩3.1bn margin 22.1% | ₩2.2bn |
| Q4 2025 derived | ₩7.7bn | +48.3% | −₩729m margin −9.5% | −₩482m |
| Q3 2025 | ₩3.9bn | -34.8% | −₩1.3bn margin −34.1% | −₩1.1bn |
| Q2 2025 | ₩8.5bn | -3.5% | −₩167m margin −2.0% | ₩182m |
| Q1 2025 | ₩13.8bn | -11.4% | ₩3.2bn margin 22.8% | ₩2.4bn |
| Q4 2024 derived | ₩5.2bn | +13.6% | −₩2.2bn margin −42.2% | −₩1.8bn |
| Q3 2024 | ₩6.0bn | +34.0% | −₩538m margin −8.9% | −₩615m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Enbio top stories 2 weeks, by number of outlets
- 1
Latest Enbio news Korean headlines
-
인바이오, 아리바이오랩에 30억원 투자…바이오 신물질 사업 확대
4 more on this story · 4 outlets
- 인바이오, 아리바이오랩에 30억원 투자…바이오 신물질 사업 확대알파경제 · Sep 16 10:07
- 인바이오, 아리바이오랩에 30억원 투자…바이오 신물질 R&D로 사업 확장더바이오 · Sep 16 10:28
- 인바이오, 아리바이오랩에 30억원 투자뉴스핌 · Sep 16 10:44
- 인바이오, 아리바이오랩에 30억 전략적 투자…신물질 사업 확대이데일리 · Sep 16 11:25